Crucial 2013 Annual Report Download - page 68

Download and view the complete annual report

Please find page 68 of the 2013 Crucial annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 130

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130

67
Equity Method Investments
As of 2013 2012
Investment
Balance Ownership
Percentage Investment
Balance Ownership
Percentage
Inotera $ 344 35% $ 370 40%
Tera Probe 40 40% — —%
Other 12 Various 19 Various
$ 396 $ 389
We recognize our share of earnings or losses from these entities under the equity method, generally on a two-month
lag. Equity in net income (loss) of equity method investees, net of tax, included the following:
For the year ended 2013 2012 2011
Inotera $ (79) $ (189) $ (112)
Other (4)(105)(46)
$ (83) $ (294) $ (158)
The summarized financial information in the tables below reflects aggregate amounts for all of our equity method
investees. Financial information is presented as of the respective dates and for the periods through which we recorded our
proportionate share of each investee's results of operations. Summarized results of operations are presented only for the periods
subsequent to the acquisition of our ownership interest.
As of 2013 2012
Current assets $ 1,018 $ 724
Noncurrent assets 2,634 3,024
Current liabilities 1,912 2,519
Noncurrent liabilities 435 155
For the years ended 2013 2012 2011
Net sales $ 1,788 $ 1,798 $ 1,839
Gross margin 1 (451)(268)
Operating loss (203)(751)(559)
Net loss (188)(793)(594)
Transform began using the liquidation basis of accounting in June 2012. Transform's statement of net assets (liabilities) in
liquidation included $9 million of assets and $8 million of liabilities as of August 29, 2013 and $29 million of assets and
$14 million of liabilities as of August 30, 2012, which were excluded from the table above. Additionally, Transform's statement
of changes in net assets (liabilities) in liquidation for the fourth quarter of 2012 included a decrease in the estimated fair values
of net assets of $67 million. Activity for 2013 was not significant. (See "Transform" below).
As of August 29, 2013, our maximum exposure to loss from our involvement with our equity method investments that
were VIEs was $344 million and primarily included our Inotera investment balance. We may also incur losses in connection
with our rights and obligations to purchase substantially all of Inotera's wafer production capacity under a supply agreement
with Inotera.